MetaCap

Protalix BioTherapeutics (DE) (PLX) vs Scribe Therapeutics (SCTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Protalix BioTherapeutics (DE) is the larger company by market cap ($244.5 million vs $228.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PLX+20.83%SCTX-36.37%
+103%+30%-43%
Jul 27, 20261 yearNov 20, 2026
PLX+22.36%SCTX-38.04%
+81%+19%-44%
Jul 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PLX versus SCTX key metrics
MetricPLXSCTX
Share price$2.90$12.07
Market cap$244.52M$228.58M
1-day change-5.23%-8.70%
YTD return+61.11%—
1-year return+65.71%—
5-year return+192.93%—
P/E ratio (TTM)12.08—
Forward P/E4.68—
EPS (TTM)$0.24$-6.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$52.74M—
Revenue growth (YoY)-1.23%—
Net income (latest FY)$-6.60M—
Gross margin48.82%—
Operating margin-10.43%—
Net margin-12.52%—
52-week high$3.19$39.60
52-week low$1.65$12.00
Distance from 52-week high-9.09%-69.52%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+313.79%+372.25%
Average volume903.48K403.27K
Shares outstanding84.32M18.94M
Employees22677
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Protalix BioTherapeutics (DE)

PLX stock →

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 226 employees

About Scribe Therapeutics

SCTX stock →

Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 77 employees

PLX vs SCTX FAQ

Which is bigger, Protalix BioTherapeutics (DE) or Scribe Therapeutics?

Protalix BioTherapeutics (DE) (PLX) is larger, with a market capitalization of $244.52M compared with $228.58M for Scribe Therapeutics (SCTX).

Are Protalix BioTherapeutics (DE) and Scribe Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons